Evidence map›Paper›PMID 26460088›Full record

SynthesisInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2015

High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012).

Mohsen Malekinejad, Soodabeh Navadeh, Ali Lotfizadeh, Afarin Rahimi-Movaghar, Masoumeh Amin-Esmaeili, Alireza Noroozi

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 6 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 6 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mohsen MalekinejadPhillip R. Lee Institute for Health Policy Studies, University of California, San Francisco, California, USA; Global Health Sciences, University of California, 3333 California Street, Suite 265, San Francisco, CA 94118, USA. Electronic address: MMalekinejad@ucsf.edu.
Soodabeh NavadehGlobal Health Sciences, University of California, 3333 California Street, Suite 265, San Francisco, CA 94118, USA; Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Ali LotfizadehPhillip R. Lee Institute for Health Policy Studies, University of California, San Francisco, California, USA.
Afarin Rahimi-MovagharIranian National Center for Addiction Studies (INCAS), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
Masoumeh Amin-EsmaeiliIranian Research Center for HIV/AIDS (IRCHA), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
Alireza NorooziDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRUniversity of California, San Francisco · US

Funding

Crucial Transitions among Young Opioid Users in IranR21DA029473 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALEKINEJAD, MOHSEN · 2010 to 2011
$322k
NIDA NIH HHS 1R21DA029473-01NIDA NIH HHS R21 DA029473
6 · The paper itself

Abstract

objectiveDrug users, particularly drug injectors, are at elevated risk of blood-borne diseases. This study systematically reviewed the prevalence of hepatitis C virus (HCV) mono-infection and its co-infections with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in drug users in Iran.

methodsSearches were conducted in international, regional, and Iranian databases. Documents were screened, data extracted, and pooled point prevalence and 95% confidence intervals (CI) were calculated.

resultsOverall, 13,821 subjects (87.4% male) with an average age of 32.4 years (95% CI 31-33 years) from 24 original studies were included in the analysis. The pooled HCV prevalence (95% CI) among drug users with and without an injection history was 45% (37-54%) and 8% (4-13%), respectively. The pooled HCV prevalences (95% CI) among individuals with vs. without a history of imprisonment and needle sharing were 58% (39-77%) vs. 44% (20-68%) and 56% (41-71%) vs. 49% (26-71%), respectively. The prevalence of HCV/HIV co-infection among injectors was 11% (95% CI 5-16%).

conclusionsHCV prevalence is high in drug users in Iran, especially among those with a history of injection drug use, needle sharing, and imprisonment. Drug user-focused HCV prevention and treatment programs are urgently needed.

Indexed as

HepacivirusHepatitis CHIV InfectionsHumansIranPrevalenceSubstance Abuse, IntravenousDrug useHarm reductionHepatitis BHepatitis CHIVIran

Identifiers

PMID26460088
PMCPMC8741151
OpenAlexW2147212974

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.